Introduction/Background When treating certain severe or recurring gynaecological malignancies, pelvic exenteration is a drastic treatment that may be used as a curative or palliative measure. As improvements have been made in surgical mortality and morbidity, its validity has changed. There has been substantial doubt and controversy around the practice of exenterative surgery. Conducting surgical studies is challenging since there is not enough information.

Methodology We retrospectively reviewed the surgical procedures and results of five patients (all with the goal of curing advanced or recurring gynaecological malignancies) who had pelvic anterior exenteration in our clinic.

Results The average age of the patients in the studied group was 58.6 years old. Regarding the diagnosis, two patients were found to have advanced stage vulvar cancer with bladder invasion, and three patients were found to have stage IIIB cervical carcinoma that had been treated with radiochemotherapy but had not shown any signs of cure. Anterior pelvectomy with derivation of the Bricker urinary reservoir was the procedure used in each instance. Radical vulvectomy was used in vulvar cancer instances. In four instances, the traditional method was used, and in one case, robotic surgery was used. In their particular scenario, the postoperative follow-up duration is between four years and four months. All of the surgical procedures were carried out without any complications occurring either during or after the procedure.

Conclusion For gynaecological malignancies, pelvic anterior exenteration is a useful and tolerable technique. These days, pelvic exenteration may be provided with low mortality and a respectable postoperative quality of life because of multimodal treatment options, extensive surgical competence, and patient preferences. We report positive first experience with robotic-assisted laparoscopic anterior pelvic exenteration, with satisfactory surgical, pathologic, and immediate clinical results. Larger experiences are undoubtedly need to fully assess and confirm this approach as a suitable surgical and oncologic choice.

Disclosures None.